Table 2. Multivariate analyses of DFS and OS of non-pCR patients with neoadjuvant chemotherapy (n = 423).
| Variables | ALL | Multivariate analyses | ||||
|---|---|---|---|---|---|---|
| DFSa | OSb | |||||
| n | % | P | HazR (95% CI) | P | HazR (95% CI) | |
| HR Conversion | 0.001 | 0.001 | ||||
| (+) to (+) | 202 | 47.8 | 1 | 1 | ||
| (−) to (−) | 143 | 33.8 | 0.411 | 1.268(0.720–2.235) | 0.596 | 1.222(0.583–2.558) |
| (+) to (−) | 55 | 13.0 | < 0.001 | 2.648(1.609–4.358) | < 0.001 | 3.460(1.738–6.885) |
| (−) to (+) | 23 | 5.4 | 0.013 | 2.400(1.206–4.776) | 0.008 | 3.834(1.416–10.377) |
| HER2 Conversion | < 0.001 | 0.003 | ||||
| (+) to (+) | 55 | 13.0 | 1 | 1 | ||
| (−) to (−) | 328 | 77.5 | 0.033 | 0.609(0.386–0.961) | 0.005 | 0.434(0.243–0.776) |
| (+) to (−) | 27 | 6.4 | 0.058 | 1.856(0.980–3.515) | 0.687 | 1.184(0.520–2.695) |
| (−) to (+) | 13 | 3.1 | 0.299 | 0.561(0.189–1.671) | 0.248 | 0.399(0.084–1.895) |
| Tumor Phenotype Conversion | < 0.001 | 0.001 | ||||
| concordant nTN | 213 | 50.3 | 1 | 1 | ||
| concordant TN | 110 | 26.0 | 0.545 | 0.862(0.532–1.395) | 0.527 | 0.825(0.454–1.498) |
| discordant nTN | 46 | 10.9 | 0.060 | 1.691(0.978–2.922) | 0.027 | 2.282(1.099–4.739) |
| discordant TN | 54 | 12.8 | < 0.001 | 2.713(1.718–4.284) | 0.003 | 2.477(1.373–4.467) |
CI: confidence interval; DFS: disease-free survival; HazR: hazard ratio; HER2: human epidermal growth factor receptor 2; HR: hormone receptor; nTN: non-triple-negative; OS: overall survival; TN: triple-negative.
a
The DFS multivariate analyses were adjusted for initial node status, NCT cycles, response to NCT, tumor size at surgery, number of positive nodes at surgery and adjuvant hormone therapy.
b
The OS multivariate analyses were adjusted for initial tumor status, initial node status, NCT regimens, tumor size at surgery, number of positive nodes at surgery and adjuvant hormone therapy.